Skip to main content
SpringerLink
Log in

Leitlinien für die Betreuung und Behandlung von Patienten mit Chorioretinopathia centralis serosa

Guidelines for the care and treatment of patients with central serous chorioretinopathy

  • konsensusbericht
  • Published:
Spektrum der Augenheilkunde Aims and scope Submit manuscript

Zusammenfassung

Die Chorioretinopathia centralis serosa (CCS) ist eine meist akut auftretende, exsudative Erkrankung der Makula, die primär junge Männer betrifft, aber auch bei Schwangeren und bei Frauen in der Menopause auftreten kann. In den meisten Fällen kommt es zu einer Spontanremission, die wahrscheinlich durch gezielte Aufklärung des Patienten erleichtert werden kann. Heilt die CCS nicht innerhalb von 3 Monaten ab, sollte die Durchführung einer photodynamischen Therapie mit reduzierter Laser- oder Medikamentendosis erwogen werden. Auf die Verordnung anderer Medikamente sollte verzichtet werden, weil es einerseits keine nachweislich wirksamen Medikamente gibt, andererseits durch Medikamenteneinnahme die wahrscheinlich viel wirksamere Veränderung des Lebensstils in den Hintergrund tritt.

Summary

Central serous chorioretinopathy is an acute exudative disease of the macula, which affects primarily young males, but can also be found in pregnant or postmenopausal females. In most cases there is a spontaneous resorption of acute exudation, which could be further improved by offering specific information to the patient. If the exudation persists longer than 3 months, a photodynamic treatment with reduced laser fluence or half dose of Verteporfin should be offered to the patient. The prescription of other medications should be avoided, since there are no medications with proved efficacy available. Using medication of any kind might also hinder an efficient change of life style, which seems to be the most effective treatment for many cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Gelber GS, Schatz H. Loss of vision due to central serous chorioretinopathy following psychological stress. Am J Psychiatry. 1987;144(1):46–50.

    Article  CAS  PubMed  Google Scholar 

  2. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008;115(1):169–73.

    Article  PubMed  Google Scholar 

  3. Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol. 2013;41(2):201–14.

    Article  PubMed  Google Scholar 

  4. Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58(2):103–26.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology. 2003;110(4):698–703.

    Article  PubMed  Google Scholar 

  6. Pastor-Idoate S, Pena D, Herreras JM. Adrenocortical adenoma and central serous chorioretinopathy: a rare association? Case Rep Ophthalmol. 2011;2(3):327–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Miki A, Kondo N, Yanagisawa S, et al. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology. 2014;121(5):1067–72.

    Article  PubMed  Google Scholar 

  8. de Jong EK, Breukink MB, Schellevis RL, et al. Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology. 2015;122(3):562–70.

    Article  PubMed  Google Scholar 

  9. Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol. 2010;149(3):361–3.

    Article  PubMed  Google Scholar 

  10. Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina. 1996;16(3):203–13.

    Article  CAS  PubMed  Google Scholar 

  11. Garg SP, Dada T, Talwar D, Biswas NR. Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol. 1997;81(11):962–4.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Wakakura M, Ishikawa S. Central serous chorioretinopathy complicating systemic corticosteroid treatment. Br J Ophthalmol. 1984;68(5):329–31.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Bouzas EA, Karadimas P, Pournaras CJ. Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol. 2002;47(5):431–48.

    Article  PubMed  Google Scholar 

  14. Chumbley LC, Frank RN. Central serous retinopathy and pregnancy. Am J Ophthalmol. 1974;77(2):158–60.

    Article  CAS  PubMed  Google Scholar 

  15. Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999;128(1):63–8.

    Article  CAS  PubMed  Google Scholar 

  16. Lovallo WR, Al’Absi M, Blick K, Whitsett TL, Wilson MF. Stress-like adrenocorticotropin responses to caffeine in young healthy men. Pharmacol Biochem Behav. 1996;55(3):365–9.

    Article  CAS  PubMed  Google Scholar 

  17. Song IS, Shin YU, Lee BR. Time-periodic characteristics in the morphology of idiopathic central serous chorioretinopathy evaluated by volume scan using spectral-domain optical coherence tomography. Am J Ophthalmol. 2012;154(2):366–75e4.

    Article  PubMed  Google Scholar 

  18. Mudvari SS, Goff MJ, Fu AD, et al. The natural history of pigment epithelial detachment associated with central serous chorioretinopathy. Retina. 2007;27(9):1168–73.

    Article  PubMed  Google Scholar 

  19. Levine R, Brucker AJ, Robinson F. Long-term follow-up of idiopathic central serous chorioretinopathy by fluorescein angiography. Ophthalmology. 1989;96(6):854–9.

    Article  CAS  PubMed  Google Scholar 

  20. Framme C, Walter A, Gabler B, et al. Fundus autofluorescence in acute and chronic-recurrent central serous chorioretinopathy. Acta Ophthalmol Scand. 2005;83(2):161–7.

    Article  PubMed  Google Scholar 

  21. Iida T, Yannuzzi LA, Spaide RF, et al. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina. 2003;23(1):1–7. (quiz 137-8).

    Article  PubMed  Google Scholar 

  22. Quaranta-El Maftouhi M, Maftouhi A E, Eandi CM. Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Am J Ophthalmol. 2015;160(3):581–7.

    Article  PubMed  Google Scholar 

  23. Gass JD, Little H. Bilateral bullous exudative retinal detachment complicating idiopathic central serous chorioretinopathy during systemic corticosteroid therapy. Ophthalmology. 1995;102(5):737–47.

    Article  CAS  PubMed  Google Scholar 

  24. Hee MR, Puliafito CA, Wong C, et al. Optical coherence tomography of central serous chorioretinopathy. Am J Ophthalmol. 1995;120(1):65–74.

    Article  CAS  PubMed  Google Scholar 

  25. Iida T, Hagimura N, Sato T, Kishi S. Evaluation of central serous chorioretinopathy with optical coherence tomography. Am J Ophthalmol. 2000;129(1):16–20.

    Article  CAS  PubMed  Google Scholar 

  26. Nicolo M, Zoli D, Musolino M, Traverso CE. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Am J Ophthalmol. 2012;153(3):474–80e1.

    Article  PubMed  Google Scholar 

  27. Teke MY, Elgin U, Nalcacioglu-Yuksekkaya P, et al. Comparison of autofluorescence and optical coherence tomography findings in acute and chronic central serous chorioretinopathy. Int. J Ophthalmol. 2014;7(2):350–4.

    Google Scholar 

  28. Yalcinbayir O, Gelisken O, Akova-Budak B, et al. Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy. Retina. 2014;34(4):705–12.

    PubMed  Google Scholar 

  29. Spaide RF, Klancnik JM Jr. Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology. 2005;112(5):825–33.

    Article  PubMed  Google Scholar 

  30. Eandi CM, Piccolino FC, Alovisi C, et al. Correlation between fundus autofluorescence and central visual function in chronic central serous chorioretinopathy. Am J Ophthalmol. 2015;159(4):652–8.

    Article  PubMed  Google Scholar 

  31. Iacono P, Battaglia PM, Papayannis A, et al. Acute central serous chorioretinopathy: a correlation study between fundus autofluorescence and spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol. 2015;253(11):1889–97.

    Article  PubMed  Google Scholar 

  32. Yoshioka H, Endo Y, Sugita T. [The study of central serous chorioretinopathy by fluorescein fundus angiography. (I)]. Nihon Ganka Gakkai Zasshi. 1969;73(3):299–305.

    CAS  PubMed  Google Scholar 

  33. Hayashi K, Hasegawa Y, Tokoro T. Indocyanine green angiography of central serous chorioretinopathy. Int Ophthalmol. 1986;9(1):37–41.

    Article  CAS  PubMed  Google Scholar 

  34. Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. Retina. 1994;14(3):231–42.

    Article  CAS  PubMed  Google Scholar 

  35. Lafaut BA, De Laey JJ. Indocyanine green angiography in central serous chorioretinopathy. Bull Soc Belge Ophtalmol. 1996;262:55–61.

    CAS  PubMed  Google Scholar 

  36. Shiraki K, Moriwaki M, Matsumoto M, et al. Long-term follow-up of severe central serous chorioretinopathy using indocyanine green angiography. Int Ophthalmol. 1997;21(5):245–53.

    Article  PubMed  Google Scholar 

  37. Chan WM, Lam DS, Lai TY, et al. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with Verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003;87(12):1453–8.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Zeligs MA. Central angiospastic retinopathy; a psychosomatic study of its occurrence in military personnel. Psychosom Med. 1947;9(2):110–7.

    Article  CAS  PubMed  Google Scholar 

  39. Lipowski ZJ, Kiriakos RZ. Psychosomatic aspects of central serous retinopathy. A review and case report. Psychosomatics. 1971;12(6):398–401.

    Article  CAS  PubMed  Google Scholar 

  40. Bernasconi P, Messmer E, Bernasconi A, Tholen A. Assessment of the sympatho-vagal interaction in central serous chorioretinopathy measured by power spectral analysis of heart rate variability. Graefes Arch Clin Exp Ophthalmol. 1998;236(8):571–6.

    Article  CAS  PubMed  Google Scholar 

  41. Tewari HK, Gadia R, Kumar D, Venkatesh P, Garg SP. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study. Invest Ophthalmol Vis Sci. 2006;47(8):3474–8.

    Article  PubMed  Google Scholar 

  42. Polak BC, Baarsma GS, Snyers B. Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment. Br J Ophthalmol. 1995;79(10):922–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Fok AC, Chan PP, Lam DS, Lai TY. Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res. 2011;46(3):160–3.

    Article  PubMed  Google Scholar 

  44. Werry H, Arends C. Untersuchung zur Objektivierung von Persönlichkeitsmerkmalen bei Patienten mit Retinopathia centralis serosa. Klin Monatsbl Augenheilkd. 1978;172(3):363–70.

    CAS  PubMed  Google Scholar 

  45. Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc. 1986;84:799–845.

    PubMed Central  CAS  PubMed  Google Scholar 

  46. Spahn C, Wiek J, Burger T, Hansen L. Psychosomatic aspects in patients with central serous chorioretinopathy. Br J Ophthalmol. 2003;87(6):704–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Conrad R, Geiser F, Kleiman A, Zur B, Karpawitz-Godt A. Temperament and character personality profile and illness-related stress in central serous chorioretinopathy. ScientificWorldJournal. 2014;2014:631687.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Gass JD. Photocoagulation treatment of idiopathic central serous choroidopathy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977;83(3 Pt 1):456–67.

    CAS  PubMed  Google Scholar 

  49. Robertson DM, Ilstrup D. Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol. 1983;95(4):457–66.

    Article  CAS  PubMed  Google Scholar 

  50. Gilbert CM, Owens SL, Smith PD, Fine SL. Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol. 1984;68(11):815–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  51. Nomura Y, Obata R, Yanagi Y. Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy. Jpn J Ophthalmol. 2012;56(3):245–9.

    Article  CAS  PubMed  Google Scholar 

  52. Cakir M, Cekic O, Yilmaz OF. Photodynamic therapy for iatrogenic CNV due to laser photocoagulation in central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging. 2009;40(4):405–8.

    Article  PubMed  Google Scholar 

  53. Chen SN, Hwang JF, Tseng LF, Lin CJ. Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology. 2008;115(12):2229–34.

    Article  PubMed  Google Scholar 

  54. Lanzetta P, Furlan F, Morgante L, Veritti D, Bandello F. Nonvisible subthreshold micropulse diode laser (810 nm) treatment of central serous chorioretinopathy. A pilot study. Eur J Ophthalmol. 2008;18(6):934–40.

    CAS  PubMed  Google Scholar 

  55. Gupta B, Elagouz M, McHugh D, Chong V, Sivaprasad S. Micropulse diode laser photocoagulation for central serous chorio-retinopathy. Clin Experiment Ophthalmol. 2009;37(8):801–5.

    Article  PubMed  Google Scholar 

  56. Koss MJ, Beger I, Koch FH. Subthreshold diode laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye (Lond). 2012;26(2):307–14.

    Article  CAS  Google Scholar 

  57. Roisman L, Magalhaes FP, Lavinsky D, et al. Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg Lasers Imaging Retina. 2013;44(5):465–70.

    Article  PubMed  Google Scholar 

  58. Malik KJ, Sampat KM, Mansouri A, Steiner JN, Glaser BM. Low-intensity/high-density subthreshold microPulse diode laser for chronic central serous chorioretinopathy. Retina. 2015;35(3):532–6.

    Article  PubMed  Google Scholar 

  59. Framme C, Alt C, Schnell S, Brinkmann R, Lin CP. [Selective RPE laser treatment with a scanned cw laser beam in rabbits]. Ophthalmologe. 2005;102(5):491–6.

    Article  CAS  PubMed  Google Scholar 

  60. Elsner H, Porksen E, Klatt C, et al. Selective retina therapy in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2006;244(12):1638–45.

    Article  CAS  PubMed  Google Scholar 

  61. Klatt C, Elsner H, Porksen E, et al. [Selective retina therapy in central serous chorioretinopathy with detachment of the pigmentary epithelium]. Ophthalmologe. 2006;103(10):850–5.

    Article  CAS  PubMed  Google Scholar 

  62. Framme C, Walter A, Prahs P, Theisen-Kunde D, Brinkmann R. Comparison of threshold irradiances and online dosimetry for selective retina treatment (SRT) in patients treated with 200 nanoseconds and 1.7 microseconds laser pulses. Lasers Surg Med. 2008;40(9):616–24.

    Article  PubMed  Google Scholar 

  63. Klatt C, Saeger M, Oppermann T, et al. Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol. 2011;95(1):83–8.

    Article  CAS  PubMed  Google Scholar 

  64. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina. 2003;23(3):288–98.

    Article  PubMed  Google Scholar 

  65. Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2003;23(6):752–63.

    Article  PubMed  Google Scholar 

  66. Canakis C, Livir-Rallatos C, Panayiotis Z, et al. Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am J Ophthalmol. 2003;136(4):750–2.

    Article  PubMed  Google Scholar 

  67. Battaglia Parodi M, Pozzo S D, Ravalico G. Photodynamic therapy in chronic central serous chorioretinopathy. Retina. 2003;23(2):235–7.

    Article  CAS  PubMed  Google Scholar 

  68. Rouvas A, Stavrakas P, Theodossiadis PG, et al. Long-term results of half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Eur J Ophthalmol. 2012;22(3):417–22.

    Article  PubMed  Google Scholar 

  69. Karakus SH, Basarir B, Pinarci EY, Kirandi EU, Demirok A. Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes. Eye (Lond). 2013;27(5):612–20.

    Article  CAS  Google Scholar 

  70. Vasconcelos H, Marques I, Santos AR, et al. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2013;251(7):1697–705.

    Article  CAS  PubMed  Google Scholar 

  71. Gutierrez-Hernandez JC, Martinez-Camarillo JC, Sadda SR. Long-term follow-up of photoreceptor loss and recovery after half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retin Cases Brief Rep. 2015;9(2):109–13.

    Article  PubMed  Google Scholar 

  72. Tseng CC, Chen SN. Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol. 2015;99(8):1070–7.

    Article  PubMed  Google Scholar 

  73. Lee JY, Chae JB, Yang SJ, Kim JG, Yoon YH. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy. Acta Ophthalmol. 2011;89(3):e293–4.

    Article  PubMed  Google Scholar 

  74. Bae SH, Heo JW, Kim C, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011;152(5):784–92e2.

    Article  CAS  PubMed  Google Scholar 

  75. Zhao M, Zhang F, Chen Y, et al. A 50 % vs 30 % dose of Verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015;133(3):333–40.

    Article  PubMed  Google Scholar 

  76. Ma J, Meng N, Xu X, Zhou F, Qu Y. System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy. Acta Ophthalmol. 2014;92(8):e594–601.

    Article  CAS  PubMed  Google Scholar 

  77. Al-Hinai AS, Al-Abri MS. Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: a case series. Oman. J Ophthalmol. 2011;4(2):63–6.

    Google Scholar 

  78. Smretschnig E, Ansari-Shahrezaei S, Moussa S, et al. Half-fluence photodynamic therapy in acute central serous chorioretinopathy. Retina. 2012;32(10):2014–9.

    Article  CAS  PubMed  Google Scholar 

  79. Lim SH, Chang W, Sagong M. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy. Eye (Lond). 2013;27(3):353–62.

    Article  CAS  Google Scholar 

  80. Nicolo M, Eandi CM, Alovisi C, et al. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol. 2014;157(5):1033–7.

    Article  PubMed  Google Scholar 

  81. Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose Verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115(10):1756–65.

    Article  PubMed  Google Scholar 

  82. Chan WM, Lai TY, Lai RY, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina. 2008;28(1):85–93.

    Article  PubMed  Google Scholar 

  83. Koytak A, Erol K, Coskun E, et al. Fluorescein angiography-guided photodynamic therapy with half-dose Verteporfin for chronic central serous chorioretinopathy. Retina. 2010;30(10):1698–703.

    Article  PubMed  Google Scholar 

  84. Kim KS, Lee WK, Lee SB. Half-dose photodynamic therapy targeting the leakage point on the fluorescein angiography in acute central serous chorioretinopathy: a pilot study. Am J Ophthalmol. 2014;157(2):366–73e1.

    Article  PubMed  Google Scholar 

  85. Shiode Y, Morizane Y, Kimura S, et al. Comparison of halving the irradiation time or the Verteporfin dose in photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2015. (Epub ahead of print).

  86. Kim YK, Ryoo NK, Woo SJ, Park KH. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015. (Epub ahead of print).

  87. Silva RM, Ruiz-Moreno JM, Gomez-Ulla F, et al. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study. Retina. 2013;33(2):309–15.

    Article  CAS  PubMed  Google Scholar 

  88. Lim JI, Glassman AR, Aiello LP, et al. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology. 2014;121(5):1073–8.

    Article  PubMed  Google Scholar 

  89. Yaman A, Arikan G, Saatci AO, Cingil G. Choroidal neovascularization following photodynamic therapy in a patient with chronic central serous chorioretinopathy. Bull Soc Belge Ophtalmol. 2007(303):69–73.

  90. Tatham A, Macfarlane A. The use of propranolol to treat central serous chorioretinopathy: an evaluation by serial OCT. J Ocul Pharmacol Ther. 2006;22(2):145–9.

    Article  CAS  PubMed  Google Scholar 

  91. Fabianova J, Porubska M, Cepilova Z. [Central serous chorioretinopathy-treatment with beta blockers]. Cesk Slov Oftalmol. 1998;54(6):401–4.

    CAS  PubMed  Google Scholar 

  92. Chrapek O, Spackova K, Rehak J. [Treatment of central serous chorioretinopathy with beta blockers]. Cesk Slov Oftalmol. 2002;58(6):382–6.

    CAS  PubMed  Google Scholar 

  93. Chrapek O, Jirkova B, Kandrnal V, Rehak J, Sin M. Treatment of central serous chorioretinopathy with beta-blocker metipranolol. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015;159(1):120–3.

    PubMed  Google Scholar 

  94. Caccavale A, Romanazzi F, Imparato M, et al. Low-dose aspirin as treatment for central serous chorioretinopathy. Clin Ophthalmol. 2010;4:899–903.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  95. Caccavale A, Romanazzi F, Imparato M, et al. Central serous chorioretinopathy: a pathogenetic model. Clin Ophthalmol. 2011;5:239–43.

    Article  PubMed Central  PubMed  Google Scholar 

  96. Chong CF, Yang D, Pham TQ, Liu H. A novel treatment of central serous chorioretinopathy with topical anti-inflammatory therapy. BMJ Case Rep. 2012;2012:pii.

    Google Scholar 

  97. Alkin Z, Osmanbasoglu OA, Ozkaya A, Karatas G, Yazici AT. Topical nepafenac in treatment of acute central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol. 2013;2(4):96–101.

    PubMed Central  PubMed  Google Scholar 

  98. Pikkel J, Beiran I, Ophir A, Miller B. Acetazolamide for central serous retinopathy. Ophthalmology. 2002;109(9):1723–5.

    Article  PubMed  Google Scholar 

  99. Nielsen JS, Jampol LM. Oral mifepristone for chronic central serous chorioretinopathy. Retina. 2011;31(9):1928–36.

    Article  CAS  PubMed  Google Scholar 

  100. Ravage ZB, Packo KH, Creticos CM, Merrill PT. Chronic central serous chorioretinopathy responsive to rifampin. Retin Cases Brief Rep. 2012;6(1):129–32.

    Article  PubMed  Google Scholar 

  101. Nelson J, Saggau DD, Nielsen JS. Rifampin induced hepatotoxicity during treatment for chronic central serous chorioretinopathy. Retin Cases Brief Rep. 2014;8(1):70–2.

    Article  PubMed  Google Scholar 

  102. Shulman S, Goldenberg D, Schwartz R, et al. Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015. (Epub ahead of print).

  103. Forooghian F, Meleth AD, Cukras C, et al. Finasteride for chronic central serous chorioretinopathy. Retina. 2011;31(4):766–71.

    PubMed Central  CAS  PubMed  Google Scholar 

  104. Bousquet E, Beydoun T, Rothschild PR, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina. 2015. (Epub ahead of print).

  105. Ryan EH, Pulido CM. Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case. Retin Cases Brief Rep. 2015;9(3):235–8.

    Article  PubMed  Google Scholar 

  106. Singh RP, Sears JE, Bedi R, et al. Oral eplerenone for the management of chronic central serous chorioretinopathy. Int. J Ophthalmol. 2015;8(2):310–4.

    Google Scholar 

  107. Salz DA, Pitcher JD 3rd, Hsu J, et al. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series. Ophthalmic Surg Lasers Imaging Retina. 2015;46(4):439–44.

    Article  PubMed  Google Scholar 

  108. Breukink MB, den Hollander AI, Keunen JE, Boon CJ, Hoyng CB. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Acta Ophthalmol. 2014;92(6):e488–90.

    Article  PubMed  Google Scholar 

  109. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007;143(6):977–83.

    Article  CAS  PubMed  Google Scholar 

  110. Chung YR, Seo EJ, Lew HM, Lee KH. Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye (Lond). 2013;27(12):1339–46.

    Article  CAS  Google Scholar 

  111. Kim DY, Joe SG, Yang SJ, et al. The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy. Korean J Ophthalmol. 2015;29(3):160–7.

    Article  PubMed Central  PubMed  Google Scholar 

  112. Kim GA, Rim TH, Lee SC, et al. Clinical characteristics of responders to intravitreal bevacizumab in central serous chorioretinopathy patients. Eye (Lond). 2015;29(6):732–40. (quiz 41).

    Article  CAS  Google Scholar 

  113. Altun A, Kurna SA, Olcaysu OO, et al. Success of ranibizumab in central serous chorioretinopathy resistant to bevacizumab. J Ocul Pharmacol Ther. 2014;30(10):842–6.

    Article  CAS  PubMed  Google Scholar 

  114. Pitcher JD 3rd, Witkin AJ, DeCroos FC, Ho AC. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br J Ophthalmol. 2015;99(6):848–52.

    Article  PubMed  Google Scholar 

  115. Broadhead GK, Chang A. Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2015;253(6):979–81.

    Article  PubMed  Google Scholar 

  116. Cunneen TS, Tridgell D. The dexamethasone suppression test for the diagnosis of Cushing syndrome in a patient with central serous chorioretinopathy. Retin Cases Brief Rep. 2013;7(2):143–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Anton-Frank-Gasse 5/4, 1180, Wien, Österreich

    Michael Stur

  2. Augenabteilung der KA Rudolfstiftung der Stadt Wien, Wien, Österreich

    Siamak Ansari-Shahrezaei

  3. Universitätsaugenklinik der Medizinische Universität Graz, Graz, Österreich

    Anton Haas

  4. Für die Netzhautkommission der Österreichischen Ophthalmologischen Gesellschaft, 1080, Wien, Österreich

    Michael Stur, Siamak Ansari-Shahrezaei, Anton Haas & Michael Tittl

Authors
  1. Michael Stur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Siamak Ansari-Shahrezaei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anton Haas
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael Tittl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Stur.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stur, M., Ansari-Shahrezaei, S., Haas, A. et al. Leitlinien für die Betreuung und Behandlung von Patienten mit Chorioretinopathia centralis serosa. Spektrum Augenheilkd. 30, 39–47 (2016). https://doi.org/10.1007/s00717-015-0276-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00717-015-0276-3

Schlüsselwörter

Keywords

Search

Navigation